| Drug General Information |
| Drug ID |
D0YX5U
|
| Former ID |
DIB020096
|
| Drug Name |
ZM-39923
|
| Synonyms |
ZM-39923
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C23H25NO
|
| InChI |
InChI=1S/C23H25NO/c1-18(2)24(17-19-8-4-3-5-9-19)15-14-23(25)22-13-12-20-10-6-7-11-21(20)16-22/h3-13,16,18H,14-15,17H2,1-2H3
|
| InChIKey |
JSASWRWALCMOQP-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
4554811, 11111983, 11114045, 15000814, 17182305, 29222916, 47216594, 47440052, 50104823, 76956277, 90340872, 103726749, 104304550, 124750043, 124881856, 124881857, 124881858, 125082357, 128319326, 139403761, 143058815, 163242903, 178102616, 179148635, 224445491, 228959517, 241056096
|
| Target and Pathway |
| Target(s) |
JAK1 |
Target Info |
Inhibitor |
[1]
|
|---|
| Tyrosine-protein kinase JAK3 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
PI3K-Akt signaling pathway
|
|
Osteoclast differentiation
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Jak-STAT signaling pathway
|
|
Leishmaniasis
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Measles
|
|
Influenza A
|
|
HTLV-I infection
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Pancreatic cancerhsa04062:Chemokine signaling pathway
|
|
Primary immunodeficiency
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Interferon-gamma signaling pathway
|
|
JAK/STAT signaling pathway
|
|
PDGF signaling pathwayP00036:Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
IL4-mediated signaling events
|
|
IL27-mediated signaling events
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IFN-gamma pathway
|
|
IL6-mediated signaling events
|
|
PDGFR-alpha signaling pathway
|
|
IL2 signaling events mediated by STAT5il4_2pathway:IL4-mediated signaling events
|
|
CD40/CD40L signaling
|
|
IL2 signaling events mediated by STAT5
|
|
Reactome
|
Interleukin-6 signaling
|
|
MAPK3 (ERK1) activation
|
|
MAPK1 (ERK2) activation
|
|
GPVI-mediated activation cascade
|
|
ISG15 antiviral mechanism
|
|
Interleukin-7 signaling
|
|
G beta:gamma signalling through PI3Kgamma
|
|
Interleukin-2 signaling
|
|
RAF/MAP kinase cascade
|
|
Interferon gamma signaling
|
|
Regulation of IFNG signaling
|
|
Interferon alpha/beta signaling
|
|
Interleukin receptor SHC signaling
|
|
Regulation of IFNA signalingR-HSA-114604:GPVI-mediated activation cascade
|
|
WikiPathways
|
Type II interferon signaling (IFNG)
|
|
Interferon type I signaling pathways
|
|
TGF Beta Signaling Pathway
|
|
IL-2 Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
IL-6 signaling pathway
|
|
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
|
|
IL-3 Signaling Pathway
|
|
Interleukin-2 signaling
|
|
Interleukin-7 signaling
|
|
JAK/STAT
|
|
PDGF Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
Prostate Cancer
|
|
TSLP Signaling Pathway
|
|
IL-9 Signaling Pathway
|
|
Type III interferon signaling
|
|
IL17 signaling pathway
|
|
IL-7 Signaling Pathway
|
|
Leptin signaling pathway
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
Interferon gamma signaling
|
|
Interferon alpha/beta signaling
|
|
IL-5 Signaling PathwayWP49:IL-2 Signaling Pathway
|
| References |
| REF 1 | Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9. |
|---|
